SCHEMBL229558

SCHEMBL229558

O=C(O)C1CCc2ccccc2O1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HSD11B1 P28845 1/20 0.45
CYP2D6 P10635 2/20 0.45
OPRK1 P41145 2/20 0.45
CA2 P00918 2/20 0.43
PPARG P37231 4/20 0.42
PPARA Q07869 3/20 0.42
PPARD Q03181 1/20 0.42
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388635 1.00 HPGD (0.49) HPGDTSHRSMN1; SMN2HDAC3HDAC1
SCHEMBL230023 1.00 HPGD (0.49) HPGDTSHRSMN1; SMN2HDAC3HDAC1
SCHEMBL27554734 1.00 HPGD (0.49) HPGDTSHRSMN1; SMN2HDAC3HDAC1
SCHEMBL2286036 1.00 HPGD (0.49) HPGDTSHRSMN1; SMN2HDAC3HDAC1
Hydrochloric Acid SCHEMBL3909230 0.98 HPGD (0.48) HPGDTSHRSMN1; SMN2HDAC3HDAC1
Methane SCHEMBL28850179 0.98 HPGD (0.48) HPGDTSHRSMN1; SMN2HDAC3HDAC1
Fluoride SCHEMBL30783508 0.98 HPGD (0.48) HPGDTSHRSMN1; SMN2HDAC3HDAC1
Hydrogen Sulfide SCHEMBL27481907 0.98 HPGD (0.48) HPGDTSHRSMN1; SMN2HDAC3HDAC1
SCHEMBL5847085 0.90 HPGD (0.50) HPGDTSHRSMN1; SMN2HDAC3HDAC1
SCHEMBL30525289 0.87 HDAC3 (0.47) HPGDTSHRHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4090654-B1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LTD (IN) 2025-07-09 EP claimed
CN-114981253-B Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2024-06-18 CN claimed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 US claimed
CN-114981253-A Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2022-08-30 CN claimed
WO-2021144814-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2021-07-22 WO claimed
CN-108148032-B Preparation method and application of 3, 4-dihydro-2H-1-benzopyran-2-carboxylic acid compound 北京海步医药科技股份有限公司 2019-12-13 CN claimed
CN-108148032-A A kind of preparation method and applications of 3,4- dihydros -2H-1- chromene -2- carboxylic acid compounds 北京海步医药科技股份有限公司 2018-06-12 CN claimed
EP-2351729-B1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ORGANIC CARBOXYLIC ACID MITSUBISHI GAS CHEMICAL CO (JP) 2014-01-22 EP claimed
CN-102203047-B Process for producing optically active organic carboxylic acid MITSUBISHI GAS CHEMICAL CO 2013-12-11 CN claimed
EP-1163010-B1 HEMOGLOBIN-ANTIOXIDANT CONJUGATES THERAPURE BIOPHARMA INC (CA) 2012-12-12 EP claimed
US-20020035276-A1 Method for producing chroman-carboxylic acid KURARAY CO., LTD. (JP) 2002-03-21 US claimed
EP-1184378-A1 Process for producing chroman-carboxylic acid Kuraray Co., Ltd. (JP) 2002-03-06 EP claimed
EP-1163010-A1 HEMOGLOBIN-ANTIOXIDANT CONJUGATES HEMOSOL INC. (CA) 2001-12-19 EP claimed
WO-2000056367-A1 HEMOGLOBIN-ANTIOXIDANT CONJUGATES HEMOSOL INC. (CA) 2000-09-28 WO claimed
US-5658796-A USING ENZYME DERIVED FROM SERRATIA SEPRACHEM, INC. (US) 1997-08-19 US claimed
WO-1996040975-A1 OPTICAL RESOLUTION OF ALKYL CHROMAN-2-CARBOXYLATES SEPRACHEM, INC. (US) 1996-12-19 WO claimed
EP-0448254-B1 Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde PFIZER (US) 1995-01-18 EP claimed
EP-0448254-A2 Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde PFIZER INC. (US) 1991-09-25 EP claimed
EP-0115142-B1 CHROMAN COMPOUNDS ICI AMERICAS INC. (US) 1986-11-05 EP claimed
EP-0115142-A1 Chroman compounds ICI AMERICAS INC. (US) 1984-08-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS CASR, CALCR, RYR1 HPGD 2248/4885TSHR 261/4885SMN1; SMN2 2582/4885
US-20020035276-A1 Method for producing chroman-carboxylic acid CDYL, DDC, CTRC HPGD 1145/4885TSHR 822/4885SMN1; SMN2 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.